Conference Track

Chronic Myeloid Leukemia

Source: CCO Independent Conference Coverage of the 2005 Annual Meeting of the American Society of Hematology*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

AMN107 Active in Imatinib-Resistant Patients With Philadelphia Chromosome–Positive CML or ALL
Dasatinib Tolerable and Effective in Imatinib-Resistant Chronic Myelogenous Leukemia
Dasatinib Active in Imatinib-Resistant/Intolerant Patients With Blast Crisis Chronic Myelogenous Leukemia (CML)
Dasatinib Effective for Philadelphia Chromosome–Positive Chronic Phase CML Patients Resistant or Intolerant to Imatinib
Dasatinib Effective for Blast Phase CML or Philadelphia Ph+ ALL Patients With Imatinib-Resistant/Intolerant Status
Residual CML Disease Levels Continue to Decline Over Time in Imatinib Responders
Maintaining Maximum Daily Dose of Imatinib in Initial Treatment Improves Response in Patients With Chronic Myeloid Leukemia
Cross-Study Comparison Suggests Imatinib Superior to Interferon/Cytarabine in Patients With CML
Combination Therapies With Imatinib Show Promise for Treatment of CML According to Interim Results
Higher-Dose Imatinib Improves Outcomes in Newly Diagnosed Patients With Chronic Myeloid Leukemia
Patients With Undetectable CML May Continue in Remission After Cessation of Imatinib
K562/GM-CSF Safely Reduces Disease Burden in Patients With Chronic Myeloid Leukemia
Cytogenetic/Molecular Responses to Imatinib Associated With Favorable Long-term Outcomes in Patients With Newly Diagnosed Chronic-Phase CML

Expert Analysis

Chronic Myeloid Leukemia

Program Director: Robert M. Rifkin, MD, FACP

Faculty:

Jane Apperley, MD
Hagop M. Kantarjian, MD
Stephen O'Brien, MB ChB, PhD

Learning Objectives

Upon completion of this activity, participants should be able to:

Review the results of recent studies using FDA-approved and investigational agents in the treatment of chronic myeloid leukemia
Discuss new insights into mechanisms by which chronic myeloid leukemia becomes resistant to imatinib therapy
Describe the impact of prognostic tools on therapeutic decision making in the treatment of chronic myeloid leukemia

CME CREDIT INFORMATION

Release Date: 02/23/06

Expiration Date: 02/22/07

Physicians: maximum of 2.0 AMA PRA Category 1 Credits™

Registered Nurses: 2.2 Nursing CE credits

Pharmacists: 2.0 contact hours (0.2 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.